2024-03-15 08:59:41 ET
Summary
- Geron's valuation may overestimate imetelstat's market impact for MDS, given FDA's moderate enthusiasm and efficacy concerns.
- FDA concerns include imetelstat's marginal efficacy, safety issues, and a non-significant improvement in patient outcomes.
- Despite FDA's apparent reservations, the advisory committee's positive vote boosts imetelstat's regulatory prospects.
- I am maintaining my "Sell" rating on GERN due to uncertainties around imetelstat's market position and impact despite the recent positive advisory vote.
A Cautious Look at Geron's Prospects Despite Advisory Nod
I last wrote on Geron ( GERN ) in December, noting that their "ideal situation appears to be already priced in."...
Read the full article on Seeking Alpha
For further details see:
Geron: Advisory Nod Boosts Approval Odds, But Market Position Remains Hazy